News from AstraZeneca
Stay current with all the latest and breaking news about AstraZeneca, compare headlines and perspectives between news sources on stories happening today. In total, 151 stories have been published about AstraZeneca which Ground News has aggregated in the past 3 months.
Covered Most By
Suggest a source
Looking for a source we don't already have? Suggest one here.Top AstraZeneca News
Latest News Stories
AstraZeneca · HungaryThe Hungarian Society of Cardiology and AstraZeneca have signed a cooperation to improve the treatment of heart failure in Hungary. During the EU Presidency, Hungary wants to develop a clear strategy to focus on cardiovascular diseases in addition to cancer diseases in health.See the Story
Heart failure is actually heart cancer, yet we don't deal with it enough
AstraZeneca · United KingdomBiopsy company Angle has signed a supplier agreement with Astrazenaca to develop technology able to detect, target and kill cancer cells. The targeted approach is more good news for cancer research – in February, Astrazenaca announced a new drug showing ‘highly impactful’ results in a lung cancer trial. Under the agreement, Angle will develop a novel technology for cancer detection using DNA damage response (DDR) tests. In 2022, the DDR therap…See the Story
Angle agrees deal with Astrazeneca for tech to kill cancer cells
AstraZenecaIn its upcoming report, Astrazeneca (NYSE: AZN) is predicted by Wall Street analysts to post quarterly earnings of $0.95 per share, reflecting a decline of 1% compared to the same period last year. Revenues are forecasted to be $11.94 billion, representing a year-over-year increase of 9.7%.See the Story
Insights Into Astrazeneca Q1: Wall Street Projections for Key Metrics - AstraZeneca (NASDAQ:AZN)
100% Center coverage: 1 sources
Amgen · Thousand OaksTuesday, Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD). Tezspire is a registered trademark of Amgen and AstraZeneca Plc (NASDAQ:AZN).
Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17%, although the reduction was not statistically significant, wi…See the Story
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)
100% Center coverage: 1 sources